

SEP 10 2007

Application No.: 10/517,722

mg-2513 (00143-00244)

IN THE CLAIMS:

1-2. (Canceled)

3. (Previously presented) The method as claimed in claim 7, characterized in that the spasmolytic includes NO or an NO source as the further spasmolytic in a therapeutically effective amount.

4. (Currently amended) The method as claimed in claim 7, wherein the xenon and the further spasmolytic are used simultaneously, separately or sequentially in the treatment of spasms.

5-6. (Canceled)

7. (Currently amended) A method of treating a patient characterized in that a xenon spasmolytic is provided in a form of a combination medicament comprising xenon selected from the group consisting of gaseous xenon and a xenon containing gas mixture, and a further spasmolytic, administering the xenon to a patient in a subanesthetic amount wherein the xenon containing gas mixture administered to the patient contains no more than 70% by volume of xenon and when the xenon-containing gas mixture itself contains more than 70% by volume xenon the xenon containing gas mixture is metered into the patient's respiratory gas so that the combined gas supplied to the patient contains from 5 to 70% by volume xenon, administering [[a]] the further spasmolytic orally or intravenously, and the combination medicament is administered to a patient as a medicament for a treatment of conditions selected from the group consisting of spasms, vasoconstrictions, cerebral vasoconstrictions, improvements of blood flow, impairments of blood flow in the brain, impairment of cerebral perfusion, coronary perfusion

Application No.: 10/517,722

mg-2513 (00143-00244)

impairment, cognitive impairments, stroke, and post-ischemia for improving the oxygen supply in the brain, for promoting blood flow in the brain, for improving the oxygenation of the body, or for improving the oxygenation of the brain, spasms, and selecting as a patient some one having such condition suffering from spasms.

8. (Currently amended) The method according to claim 7, wherein the xenon is used to produce a combination medicament having has a vasodilating effect in capillary or precapillary vascular systems of the human body.

9-17. (Canceled)

18. (New) The method according to claim 7, wherein the spasms are selected from the group consisting of vasospasms and cerebral vasospasms.